Ankasa Regenerative TherapeuticsDeveloping novel protein-based stem cell activation therapies to improve tissue repair and regeneration
Ankasa Regenerative TherapeutisDeveloping novel protein-based stem cell activation therapies to improve tissue repair and regeneration
Stem cell renewal, maintenance and tissue regeneration are critical for normal health and well-being. Wnt pathway interactions are crucial to maintenance of these processes. Ankasa is the first to produce human Wnt proteins in a manufacturing setting suitable for use in humans.
Our first clinical approach will be the demonstration of improved outcomes after spinal fusion surgeries. Our product has expansion opportunities to other bone reconstructive procedures including osseointegration of dental and orthopedic implants (knee and hip replacements), fracture repair, total joint arthroplasty revisions, and others.
Ankasa is developing ART352-L as a novel regenerative medicine. Successful development of ART352-L will enhance the osteogenic properties of patient derived stem cells used in reconstructive surgeries and provide safe and effective enhancement of bone formation in indications for which this is a significant unmet medical need.
Ankasa’s lead indication is augmentation of autograft used in spinal fusion for treatment of degenerative changes in intervertebral discs, a highly prevalent chronic, debilitating condition that can severely impact day-to-day functioning. Our preclinical data suggest that treatment of a patient’s autograft with ART352-L will generate significantly more bone without unwanted bone overgrowth, thus reducing the rate of revision surgeries and their attendant complications. This is a direct benefit to the target patient population as well as a direct savings to the healthcare system.
Ankasa has raised over $19M from a venture investment syndicate, led by Avalon Ventures and including Heraeus Medical GmbH, Correlation Ventures and Stanford University. We have also been awarded over $6M from The California Institute of Regenerative Medicine (CIRM) in two grants to support pre-clinical research and our Investigational New Drug (IND) submission.
Management Team & Key People
Sanford J. Madigan, Ph.D.
Co-Founder, Chief Executive Officer
Gloria Matthews, DVM, Ph.D., DACVS
Chief Medical Officer
Jill Helms, D.D.S., Ph.D.
Co-Founder, Senior Advisor
Scientific Advisory Board
David Lacey, M.D.
Co-Founder, Chair SAB
Roland Baron, D.D.S., Ph.D.
Professor and Chair, Department of Oral Medicine
Harvard School of Dental Medicine
Phillip Leucht, M.D.
Associate Professor, Department of Orthopaedic Surgery
Associate Professor, Department of Cell Biology
NYU Langone Health, Langone Orthopedic Hospital
© 2019 Ankasa. All Rights Reserved